A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe Ulcerative Colitis
Read time: 1 mins
Last updated:27th Nov 2008
The primary Objective for the Induction Phase is to determine the effect of MLN0002 induction treatment on clinical response at 6 weeks. The primary Objective for the Maintenance Phase is to determine the effect of MLN0002 maintenance treatment on clinical remission at 52 weeks.
|Study start date||2008-11-27|